Why the study?
Do CHA2DS2-VASc and HAS-BLED scores improve risk prediction for ischaemic stroke and bleeding compared to CHADS2 and HEMORR2HAGES in patients with atrial fibrillation?
Do CHA2DS2-VASc and HAS-BLED scores improve risk prediction for ischaemic stroke and bleeding compared to CHADS2 and HEMORR2HAGES in patients with atrial fibrillation?
No takes yet. Share an insight, caveat, or question.
While CHA2DS2-VASc improves identification of truly low-risk AF patients, its broad application categorizes nearly all others as high risk, and bleeding scores should not be used in isolation to withhold anticoagulation.
Piccini et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: